Congrats to Pedro C Barata, MD MSc FACP Sumanta K. Pal, MD, FASCO and the entire team for the final OS analysis from the PAPMET trial! Though there is no significant OS difference, cabozantinib remains a solid option for advanced Papillary RCC. The need for novel therapies is clear! ASCO Journal of Clinical Oncology @oncoalert